
商务合作

动脉网APP
可切换为仅中文
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affiliate has acquired Elios Vision, Inc., developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser.
。
The acquisition unlocks new opportunities to treat glaucoma effectively in conjunction with cataract surgery without implants and bolsters Bausch + Lomb’s glaucoma portfolio, which features pharmaceutical and surgical approaches.“Today’s announcement further demonstrates our commitment to investing in smart, innovative technologies that enable eye care professionals to better address the evolving needs of their patients,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb.
此次收购为无需植入物的白内障手术提供了有效治疗青光眼的新机会,并巩固了博士伦公司的青光眼产品组合,该组合以药物和手术方法为特色。博士伦医院外科总裁Luc Bonnefoy表示:“今天的公告进一步表明,我们致力于投资智能创新技术,使眼科护理专业人员能够更好地满足患者不断变化的需求。”
“The ELIOS system offers a differentiated approach for the treatment of glaucoma, a condition expected to increase in prevalence by 47% from 2020 to 2040.”1Compared to other glaucoma surgery techniques, MIGS offers a safe and effective approach to lowering intraocular pressure with faster recovery time.2 It can also often be performed in conjunction with cataract surgery, the most routinely performed surgery in the world.3 More than 19% of patients who need cataract surgery also have glaucoma or ocular hypertension4; cataract surgery provides an optimal opportunity for concurrent glaucoma treatment.“ELIOS provides a tissue-friendly, precision non-thermal laser-based and highly adoptable procedure for the treatment of glaucoma,” said Professor Ike K.
“ELIOS系统为青光眼的治疗提供了一种有区别的方法,预计2020年至2040年,青光眼的患病率将增加47%。”1与其他青光眼手术技术相比,MIGS提供了一种安全有效的降低眼压的方法,恢复时间更快。2它也可以经常与白内障手术(世界上最常规的手术)联合进行。3需要白内障手术的患者中,有19%以上患有青光眼或眼压过高4;白内障手术为并发青光眼治疗提供了最佳机会。“ELIOS为青光眼的治疗提供了一种组织友好、精确、基于非热激光的高度可接受的方法,”IkeK教授说。
Ahmed, MD, University of Toronto and Moran Eye Center. “The synergy between cataract surgery and MIGS can help ophthalmologists provide streamlined care and improve patient quali.
多伦多大学和莫兰眼科中心医学博士艾哈迈德。“白内障手术和MIGS之间的协同作用可以帮助眼科医生提供简化的护理并提高患者的质量。
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments.
博士伦致力于保护和增强世界各地数百万人的视力,从出生到生命的每个阶段。其大约400种产品的综合组合包括隐形眼镜、镜片护理产品、眼部护理产品、眼科药物、非处方产品以及眼科手术设备和仪器。
Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.About Elios Vision, Inc..
博士伦公司成立于1853年,在全球拥有重要的研发、制造和商业足迹,拥有约13000名员工,业务遍及近100个国家。博士伦总部位于安大略省沃恩,公司办事处位于新泽西州布里奇沃特。有关更多信息,请访问www.bausch.com,并通过X、LinkedIn、Facebook和Instagram与我们联系。关于Elios Vision,Inc。
Elios Vision Inc. is a privately held company, working to preserve sight by developing a safe and effective breakthrough solution for the millions of patients who have glaucoma.Forward-looking Statements
Elios Vision Inc.是一家私营公司,致力于为数百万青光眼患者开发安全有效的突破性解决方案,以保护视力。前瞻性声明
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions.
本新闻稿可能包含前瞻性陈述,这些陈述通常可以通过使用“预期”、“希望”、“预期”、“打算”、“计划”、“应该”、“可能”、“会”、“会”、“会”、“可能”、“相信”、“估计”、“潜在”、“目标”或“继续”等词语以及变体或类似表达来识别。
These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S.
这些声明基于管理层当前的期望和信念,并受到某些风险和不确定性的影响,这些风险和不确定性可能导致实际结果与前瞻性声明中描述的结果存在重大差异。这些风险和不确定性包括但不限于博士伦向美国提交的文件中讨论的风险和不确定性。
Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.References:1 Allison K, Patel D, Alabi O.
证券交易委员会和加拿大证券管理人,这些因素通过引用纳入本文。提醒读者不要过度依赖这些前瞻性陈述。。博士伦没有义务更新任何前瞻性声明,以反映本新闻发布日期后的事件或情况,或反映实际结果,除非法律要求。参考文献:1 Allison K,Patel D,Alabi O。
Cureus. 2020 Nov 24..
库鲁斯。2020年11月24日。。
2 Gao X, Lv A, et al. BMJ Open. 2022 Jul 4;12(7):e062441. doi: 10.1136/bmjopen-2022-062441. PMID: 35788072; PMCID: PMC9255398.
2高X,吕安,等。英国医学杂志公开赛。2022年7月4日;12(7):e062441。doi:10.1136/bmjopen-2022-062441。PMID:35788072;PMCID:PMC9255398。
3 McGhee, CNJ, Zhang, J, Patel, DV. J Royal Society NZ, 2020 Jan.
3 McGee,CNJ,Zhang,J,Patel,DV。J新西兰皇家学会,2020年1月。
4 Tseng, VL, Yu, F, et al. JAMA. 2012 Aug. 1.© 2024 Bausch + Lomb.View source version on businesswire.com: https://www.businesswire.com/news/home/20241211687982/en/Media Contact:
4 Tseng,VL,Yu,F等。JAMA。2012年8月1日©2024 Bausch+Lomb。在businesswire.com上查看源版本:https://www.businesswire.com/news/home/20241211687982/en/Media联系人:
Caryn Marshall
卡琳 马歇尔
caryn.marshall@bausch.com
caryn.marshall@bausch.com
(908) 493-1381Investor Contact:
(908)493-1381 Investor触点:
George Gadkowski
乔治 Gadkowski
george.gadkowski@bausch.com
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
(877)354-3705(免费电话)
(908) 927-0735Source: Bausch + Lomb Corporation
(908)927-0735来源:博士伦公司